ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's ...
ProQR Therapeutics N.V. (Nasdaq: PRQR) is a biotech company dedicated to creating potentially life-changing RNA-based therapies for patients with severe rare and common diseases, with a particular emphasis on genetic disorders. Headquartered in Leiden, the Netherlands, ProQR’s strategy centers on developing therapeutics that address disease-causing genetic variants through RNA-directed approaches, ...ProQR Therapeutics N.V. (Nasdaq: PRQR) is a biotech company dedicated to creating potentially life-changing RNA-based therapies for patients with severe rare and common diseases, with a particular emphasis on genetic disorders. Headquartered in Leiden, the Netherlands, ProQR’s strategy centers on developing therapeutics that address disease-causing genetic variants through RNA-directed approaches, rather than conventional protein replacement or small-molecule pathways.
At the product and pipeline level, ProQR’s portfolio includes clinical-stage RNA therapy candidates. Sepofarsen is being evaluated in a Phase II/III program (the ILLUMINATE trial) targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also in Phase II/III evaluation for conditions associated with USH2A-mediated retinitis pigmentosa and Usher syndrome (US H syndrome). These programs reflect ProQR’s focus on advancing therapies where RNA-targeting may enable modulation of underlying genetic mechanisms.
Underpinning the pipeline is ProQR’s proprietary Axiomer RNA base-editing platform technology. From a business perspective, this platform supports both internal program development and external partnerships by providing a differentiated technical foundation for discovery and translational research. ProQR’s approach includes licensing and collaboration arrangements with academic and industry partners—such as agreements involving Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, and Leiden University Medical Center—plus a notable license and research partnership with Eli Lilly focused on discovering, advancing, and commercializing medicines for genetic conditions affecting the liver and nervous system.
Cost and operational structure in this sector typically relies heavily on research and development rather than manufacturing-heavy cost of goods. ProQR’s financial metrics (as presented in the dataset) suggest a R&D-intensive model with limited or negative cash-flow generation at this stage, which is common for clinical-stage biotechnology companies where expenses for trials, regulatory work, CMC-related development, and platform operations precede product revenues. In this context, “BOM” is not a traditional bill-of-materials manufacturing model; instead, the cost base includes trial operations, specialized laboratory work, analytical development, regulatory submissions, and platform engineering—often complemented by collaboration arrangements that can share certain scientific or development responsibilities.
In terms of key people, Daniel Anton de Boer serves as the founder and CEO, having led the company since its incorporation in 2012. With a workforce of about 187 employees, ProQR has a relatively compact organization for late pre-commercial development, consistent with a specialty biotech model that leverages external partners and scientific networks.
Looking ahead, ProQR’s success depends on continued clinical progress, regulatory outcomes, and the ability to translate RNA-editing platform capabilities into robust therapeutic candidates. The company’s collaboration-driven strategy is designed to broaden opportunities across therapeutic areas and disease targets while maintaining focus on advancing its key internal programs.
